Therapy News and Research

RSS

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery.

16 Jul 2007

A suntan is the body's best effort to fend off ultraviolet light

For years, the official word on tanning has been … don't. Health organizations have driven home the message that the sun exposure needed to get a tan increases your chances of getting skin cancer.

16 Jul 2007

Co-operation between GSF and clinic improves outlook for sarcoma patients

Hyperthermia, combined with chemotherapy, improves the chances of healing and survival of patients with low-lying, soft tissue sarcomas. At the Annual General Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, the GSF scientist Prof. Dr Rolf D.

16 Jul 2007

Hope for cure for insulin-dependent diabetes

A diagnosis of type I diabetes means a life sentence of medical follow-up. While treatments have become simpler and less restrictive in recent years, they are still a burden, especially for young patients.

16 Jul 2007

Src inhibitors may prove beneficial in breast cancer therapy

Estrogen, which binds estrogen receptor alpha (ER-alpha), is a risk factor for breast cancer development.

13 Jul 2007

Sciton receives FDA approval for laser-assisted lipolysis and pulsed light treatment of wrinkles

Sciton has announced that the new ProLipo laser module received clearance from the U.S. Food and Drug Administration for laser-assisted lipolysis, and its BBL broadband pulsed light received clearance for the treatment of wrinkles.

13 Jul 2007

Discovery of one important function of junk DNA

Scientists have only recently begun to speculate that what's referred to as junk DNA , the 96 percent of the human genome that doesn't encode for proteins and previously seemed to have no useful purpose , is present in the genome for an important reason.

13 Jul 2007

New target for muscular dystrophy drug therapy

Researchers at the University of Pennsylvania School of Medicine report how the gene for utrophin, which codes for a protein very similar to dystrophin, the defective protein in Duchenne muscular dystrophy (DMD), puts the brakes on its own expression in muscle cells, thereby suggesting a new target for treatment.

13 Jul 2007

Clinical responses to antiretroviral drug therapy simulated for the first time

Treatment of HIV patients must balance the need to suppress viral replication against the harmful side effects and significant cost to the patient of antiretroviral therapy.

13 Jul 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007

UAB receives grants to investigate novel approaches to treat Parkinson's disease

The Michael J. Fox Foundation (MJFF) has awarded two research grants to UAB (University of Alabama at Birmingham) researchers to investigate novel approaches to treat Parkinson's disease.

13 Jul 2007

Wilmot Cancer Center studies new chemo pill for lymphoma

Doctors at the University of Rochester's James P. Wilmot Cancer Center are first in the world to study a new, targeted agent that zeroes-in on B-cell lymphomas. The new twice-a-day pill offers patients with recurrent disease another choice as their options grow thin.

12 Jul 2007

St. Jude study holds promise for improving neuroblastoma treatment

A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one, according to results of studies at St. Jude Children's Research Hospital.

12 Jul 2007

Startling discovery on the development of human embryonic stem cells

In this week's Nature, researchers of the McMaster Cancer and Stem Cell Research Institute show that human embryonic stem (ES) cells can actually produce distinctive niche cells, which then release stem-cell nourishing proteins to help keep their parents ticking over.

12 Jul 2007